Acquisition Opportunity StrataDx was recently acquired by Fulgent Genetics for combined asset value around $55.5M, suggesting a potential sales opening to align with the new ownership priorities, integrate with Fulgent’s broader diagnostic network, and pursue cross-sell of StrataDx’s pathology services to Fulgent’s customer base.

Data Security Risk A disclosed data breach involving sensitive personal information in July 2026 highlights an immediate need for enhanced data governance and security offerings, creating a pathway for selling advanced cybersecurity, compliance, and incident response solutions to restore trust and mitigate risk.

DermSTAT Growth Historical launch of DermSTAT skin infection DNA tests signals openness to innovative molecular diagnostics; there is an opportunity to upsell complementary molecular pathology services, genomic sequencing capabilities, and targeted assay development to expand the test menu.

Scale Fit Current employee base (51-200) and mid-market position align with scalable service contracts; potential for managed pathology services, dedicated client support models, and bundled lab services to larger health systems seeking reliable, consistent turnaround times.

Market Positioning As a long-standing pathology lab with a national footprint and notable leadership, StrataDx can be positioned for strategic collaborations with larger genetics and diagnostics firms, offering specialty pathology expertise, second-opinion services, and targeted diagnostic solutions to competitive players in the sector.